Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.

You may also be interested in...



Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In

The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion

Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In

The potential for combination therapy involving direct-acting antivirals in the growing hepatitis C space has garnered significant attention from industry firms big and small. At present, even though the standard of care - ribavirin plus one of two branded pegylated interferons (Roche's Pegasys and Schering-Plough's Pegintron) - is effective only in about half of all HCV patients, those drugs generate annual net sales of roughly $2.5 billion

Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate

Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel